Oncology Central

Intratumor heterogeneity: predicting and preventing therapeutic resistance


Despite dramatic advances and widespread clinical adoption of genetic testing for the identification of interpatient genetic variation, treatment with targeted drugs and temporary effectiveness, these agents only prolong survival for a few months [1]. Recent data suggest that shifting from single biopsy-based testing to comprehensive intratumor diversity using next-generation sequencing (NGS) technologies could reduce tumor resistance to modern therapy. Could intratumor heterogeneity be used as a biomarker to predict primary tumor responsiveness and improve initial systemic treatment?

To view restricted content, please:

Leave A Comment